publication date: Mar. 28, 2014
FDA Advisory Panel Unanimously Favors New Stool DNA Colorectal Screening Test
The FDA Molecular and Clinical Genetics Panel voted 10-0 to recommend approval of Cologuard—a noninvasive, multitarget stool DNA screening test for colorectal cancer.
Sponsored by Exact Sciences Corp., Cologuard outperformed a standard fecal immunochemical test in a study published March 19 in the New England Journal of Medicine.
|Rising Costs at NCI Threaten to Overtake |
Slim Increases In Budget Appropriations
Sometimes a funding increase can be no increase at all.
NCI’s budget was increased by 2.8 percent for the current 2014 fiscal year, or about $134 million, restoring about 53 percent of previous cuts made by sequestration. The institute’s total budget stands at $4.9 billion.
Caplan Receives NSB Public Service Award
Fazio and Kantarjian Receive Lifetime Achievement Awards
Pienta named director of Johns Hopkins Prostate Cancer Program
American Society of Hematology awards 15 bridge grants
Stewart named incoming president of Patient Advocate Foundation
Ohio State signs agreement with MedVax Technologies Inc.
UC San Francisco signs agreement with Advaxis Inc.
Georgia Regents receives CEO Gold Standard accreditation
The winners of the Research!America Advocacy Awards
European Commission approves MabThera SC
Japan approves LonSurf combination tablet